- Clinical Trials
© 2023 © 2020 Genprex Inc. All Rights Reserved.
Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.
The abstract reports NPRL2 gene therapy induces effective anti-tumor activity in non-small cell lung cancer pembrolizumab resistant tumors in a humanized mouse model and provides preclinical validation of the ONCOPREX® Nanoparticle Delivery System with a second tumor suppressor gene
Data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) on February 25, 2023 in Berlin, Germany.
A one-page fact sheet and overview of Genprex.
A bibliography of selected publications describing the TUSC2 gene.
A bibliography of selected publications describing the PDX1 and MAFA genes.
The poster presents positive preclinical data for REQORSA in combination with Tagrisso®, demonstrating synergistic antitumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.
The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.
The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.
The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.
The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.
The poster describes a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanoparticle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.
The poster presents data on the synergistic antitumor activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC.
We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.